Nuvectis Pharma

NVCT · NASDAQ

$20.59+$1.65 (+8.71%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $18.94

NVCT analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $36.11 (+75.4% upside)

Low: $30.30
Now: $20.59
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

NVCT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 24, 2026	Maintains	Buy	$39.00	40%
Cantor Fitzgerald	Aug 24, 2026	Initiates	Overweight	—	28%
Roth Capital	Jul 6, 2026	Maintains	Buy	$20.00 → $33.00	25%
HC Wainwright & Co.	Jun 22, 2026	Maintains	Buy	$13.00 → $39.00	40%
HC Wainwright & Co.	Jun 12, 2026	Maintains	Buy	$10.00 → $13.00	40%

The case for and against

Updated Oct 21, 2026

Bull case

Nuvectis Pharma is attractive because its in-licensed assets expand the story beyond a single oncology program into two differentiated, clinically supported value drivers: NXP100 in complement-mediated disease and NXP200 in precision oncology. NXP100 has compelling Phase 3 data in China, ongoing regulatory review for PNH, and a once-daily oral profile versus Fabhalta’s twice-daily dosing, while the company’s $768M market cap appears to underappreciate the >$1B annual peak sales potential cited for PNH alone. NXP200 adds further upside through China Breakthrough Therapy Designation for high-grade glioma, >40% response rate in low- and high-grade adult glioma, and durable activity across multiple BRAF-altered tumors, supporting a broader, catalyst-rich pipeline.

Bear case

Nuvectis Pharma is a highly speculative oncology developer whose value depends on a small set of early-stage assets, with NXP100, NXP200, and NXP900 each assigned only partial probability of success in the valuation model. While positive China pivotal data, a filed MAA, and Phase 2 IgAN results support some upside, the thesis remains fragile because clinical net present value assumptions can reverse quickly if later trials are failed or inconclusive. The company also faces meaningful financing risk, since advancing later-stage programs and expanding beyond current indications may require significant, potentially dilutive capital raises before any commercial revenue is established.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.